CY1933A - Novel compounds - Google Patents

Novel compounds

Info

Publication number
CY1933A
CY1933A CY193390A CY193390A CY1933A CY 1933 A CY1933 A CY 1933A CY 193390 A CY193390 A CY 193390A CY 193390 A CY193390 A CY 193390A CY 1933 A CY1933 A CY 1933A
Authority
CY
Cyprus
Prior art keywords
novel compounds
anchor
less
gpiii
gpii
Prior art date
Application number
CY193390A
Other languages
English (en)
Inventor
Alex Bollen
Diane Gregoire
Michel Heinderckx
Paul Jacobs
Marc Massaer
Original Assignee
Smithkline Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Biolog filed Critical Smithkline Biolog
Publication of CY1933A publication Critical patent/CY1933A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrically Driven Valve-Operating Means (AREA)
  • Piezo-Electric Or Mechanical Vibrators, Or Delay Or Filter Circuits (AREA)
  • Liquid Crystal (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY193390A 1989-06-27 1990-06-22 Novel compounds CY1933A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37177289A 1989-06-27 1989-06-27

Publications (1)

Publication Number Publication Date
CY1933A true CY1933A (en) 1990-06-22

Family

ID=23465352

Family Applications (1)

Application Number Title Priority Date Filing Date
CY193390A CY1933A (en) 1989-06-27 1990-06-22 Novel compounds

Country Status (15)

Country Link
EP (1) EP0405867B1 (ko)
JP (1) JPH0349694A (ko)
KR (1) KR0166585B1 (ko)
AT (1) ATE119939T1 (ko)
AU (1) AU625328B2 (ko)
CA (1) CA2019845A1 (ko)
CY (1) CY1933A (ko)
DE (1) DE69017769T2 (ko)
DK (1) DK0405867T3 (ko)
ES (1) ES2071770T3 (ko)
HK (1) HK1006468A1 (ko)
IE (1) IE66516B1 (ko)
NZ (1) NZ234222A (ko)
PT (1) PT94479B (ko)
ZA (1) ZA904915B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824319A (en) * 1990-10-04 1998-10-20 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
DE69132404T2 (de) 1990-10-04 2001-02-15 Research Corp. Technologies, Inc. Varicella-zoster virusantigen
JP4562812B2 (ja) * 1992-07-17 2010-10-13 メルク・シャープ・エンド・ドーム・コーポレイション 帯状疱疹の予防または水痘関連ヘルペス後神経痛の緩和方法
GB9226768D0 (en) * 1992-12-23 1993-02-17 Smithkline Beecham Biolog Vaccines
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
US5834441A (en) * 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
KR970006484A (ko) * 1995-07-27 1997-02-21 수두 바이러스의 당단백질을 대량발현시키는 동물세포주
US7112331B2 (en) 1996-02-09 2006-09-26 Smithkline Beecham Biologicals, S.A. Vaccines against varicella zoster virus gene 63 product
EP0879060B1 (en) * 1996-02-09 2008-03-26 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines against varicella zoster virus gene 63 product
KR100434023B1 (ko) * 1996-02-29 2005-05-09 주식회사 엘지생명과학 수두바이러스의당단백질을대량발현시키는동물세포주
DE19757767A1 (de) 1997-12-23 1999-07-15 Dade Behring Marburg Gmbh Immunreaktive Bereiche des Glycoproteins gpII des Varicella-Zoster-Virus (VZV)
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
BR112019011286A2 (pt) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals Sa métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CN110621339A (zh) 2017-04-28 2019-12-27 葛兰素史密丝克莱恩生物有限公司 疫苗接种
IE87439B1 (en) 2017-05-30 2023-10-11 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
CN112142829B (zh) * 2019-06-28 2022-02-22 怡道生物科技(苏州)有限公司 水痘-带状疱疹病毒gE蛋白突变体及其表达方法
CN115819616A (zh) * 2021-07-28 2023-03-21 江苏瑞科生物技术股份有限公司 一种基因重组vzv融合蛋白及其制备方法和应用
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
ATE230798T1 (de) * 1984-04-06 2003-01-15 Chiron Corp Rekombinanter herpes simplex gb-gd-impfstoff
US4769239A (en) * 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
EP0211756A1 (en) * 1985-08-01 1987-02-25 Merck & Co. Inc. Assay for varicella-zoster virus (VZV) antibodies
US4686101A (en) * 1985-08-02 1987-08-11 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4952674A (en) * 1986-05-02 1990-08-28 Merck & Co., Inc. Vaccine against varicella-zoster virus
KR890701745A (ko) * 1987-06-30 1989-12-21 원본미기재 O-결합 글리코실화가 감소된 바이러스 단백질

Also Published As

Publication number Publication date
EP0405867B1 (en) 1995-03-15
NZ234222A (en) 1992-03-26
ES2071770T3 (es) 1995-07-01
PT94479B (pt) 1997-05-28
JPH0349694A (ja) 1991-03-04
DK0405867T3 (da) 1995-05-22
IE66516B1 (en) 1996-01-10
AU5779290A (en) 1991-01-03
DE69017769T2 (de) 1995-07-13
KR0166585B1 (ko) 1999-01-15
IE902297A1 (en) 1991-01-16
HK1006468A1 (en) 1999-02-26
AU625328B2 (en) 1992-07-09
ATE119939T1 (de) 1995-04-15
PT94479A (pt) 1991-02-08
ZA904915B (en) 1991-06-26
DE69017769D1 (de) 1995-04-20
CA2019845A1 (en) 1990-12-27
IE902297L (en) 1990-12-27
KR910001060A (ko) 1991-01-30
EP0405867A1 (en) 1991-01-02

Similar Documents

Publication Publication Date Title
CY1933A (en) Novel compounds
AU2618088A (en) Fowlpox virus promoters
IT1229845B (it) Procedimento per la preparazione di perfluoropolieteri perossidici.
DE69007691D1 (de) Verfahren zur Herstellung von Alkylaluminoxanen.
DE59409751D1 (de) Verfahren zur Herstellung von hydroxyphenylsubstituierten 1,3,5-Triazinen
GB8700146D0 (en) Molecular beam source
DE69011202D1 (de) Radio-opaker Klebstoff/radio-opake Dichtung zur Detektion von Lücken.
AU599161B2 (en) Heat resistant resin composition by suspension polymerization
AU5639390A (en) Gangliotetraosylceramide as an adsorbent for enteric viral pathogens
AU6420390A (en) N-alkyl-p-quinonediimino triazine compounds
AU9121182A (en) Vorrichtung zur durchfuhrung von physiologischen uebungen mit aktiven und passiven bewegungen
IT9019723A0 (it) Procedimento per la modificazione di copolimeri di acrilato
EP0405905A3 (en) Use of isoxazolin-3-one derivatives as antidepressants
DE68918055D1 (de) Verfahren zur Abtrennung von Phenol.
FI960526A0 (fi) Menetelmä kumeenihydroperoksin valmistamiseksi
GB8917059D0 (en) Avipox virus promoters
AU4545285A (en) Verfahren und vorrichtung zur reinigung von textilien, insbesondere von teppichen
DE59006193D1 (de) Verfahren zur Hestellung von 4-Methylentetrahydropyran.
IT1229510B (it) Procedimento per la preparazione di alfa bromoalcilfluoruri.
EP0431472A3 (en) Resin compositions for light control sheets, and light control sheets prepared from said compositions
EP0431974A3 (en) Light beam deflector
IT1243446B (it) Procedimento di disturbo iff per elicotteri
ATE109124T1 (de) Verfahren zur enantiomerentrennung von benzopyranderivaten.
FI904321A0 (fi) Anordning foer omplacering och aoterplacering av en videosignal.
GB8912569D0 (en) Ion beam source